Tag Archive for: Evofem

Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone. Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity. These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely.

Pharma companies are striving to convey the true impact of diseases on patients while continuing to empower them.

Evofem’s bold campaign surrounding the first hormone-free contraception gel for women helped the company bring home leading industry awards and elevated Phexxi to the top prescription brand in the 2022 OCI. Katherine Atkinson, chief commercial officer at Evofem Biosciences, walked Med Ad Newsthrough the company’s conceptual journey of the campaign and what it meant to give women more control over their bodies – and their sexual and reproductive health.